---
document_datetime: 2025-12-02 05:01:51
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/wilzin.html
document_name: wilzin.html
version: success
processing_time: 0.1079695
conversion_datetime: 2025-12-25 04:18:43.653342
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Wilzin

[RSS](/en/individual-human-medicine.xml/66542)

##### Authorised

This medicine is authorised for use in the European Union

zinc Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Wilzin](#more-information-on-wilzin-720)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).

Expand section

Collapse section

## What is Wilzin?

Wilzin is a medicine that contains the active substance zinc. It is available as capsules (blue: 25 mg; orange: 50 mg).

## What is Wilzin used for?

Wilzin is used to treat Wilson's disease. Wilson's disease is a rare inherited disorder where patients lack an enzyme that is needed to eliminate the copper contained in food from the body. This results in copper building up in the body, first in the liver, then in other organs such as the eye and the brain. This causes a variety of effects, including liver disease and damage to the nervous system.

Because the number of patients with Wilson's disease is low, the disease is considered 'rare', and Wilzin was designated an 'orphan medicine' (a medicine used in rare diseases) on 31 July 2001.

The medicine can only be obtained with a prescription.

## How is Wilzin used?

Wilzin treatment should be started by a doctor who has experience in the treatment of Wilson's disease.

The usual dose for adults is 50 mg three times a day. A reduced dose is used in children. Wilzin should be taken on an empty stomach, at least one hour before or two to three hours after meals. Wilzin is a long-term treatment. Patients who are switching from a 'chelating agent' (another type of medicine for Wilson's disease) to Wilzin should continue to take the chelating agent for two to three weeks after starting Wilzin, because Wilzin takes some time to start working fully. The maximum dose of Wilzin is 50 mg five times a day. For more information, see the package leaflet.

## How does Wilzin work?

The active substance in Wilzin is the zinc cation (positively charged zinc), which blocks the absorption of copper from the diet. It works by stimulating the body to produce a protein called metallothionein in the cells lining the gut. This protein attaches to copper and prevents it being transferred into the blood. The copper is then passed out of the body in the stools. Over time, the amount of copper in the body falls, improving the symptoms of the disease. Zinc has been used to treat Wilson's disease since 1958.

## How has Wilzin been studied?

Because zinc has been used to treat Wilson's disease for many years, the company presented the results of studies from the published literature. In total, data to support the use of Wilzin came from 255 patients with Wilson's disease. The main study involved 148 patients who were treated with Wilzin, but did not compare Wilzin with any other treatments. The main measure of effectiveness was whether patients had adequate control of copper levels.

## What benefit has Wilzin shown during the studies?

Wilzin has been shown to be effective in reducing the absorption of copper and reducing the amount of copper in the body. In the main study, 91% of the patients evaluated (91 out of 100) had adequate control of their copper levels within the first year of treatment with Wilzin.

## What is the risk associated with Wilzin?

The most common side effects with Wilzin (seen in between 1 and 10 patients in 100) are gastric irritation (irritation of the stomach) and increased blood levels of enzymes (amylase, lipase and alkaline phosphatase). Gastric irritation is usually worst with the first morning dose and disappears after the first few days of treatment. Delaying the first dose to mid-morning or taking the dose with a small amount of food containing protein, such as meat, may help. For the full list of all side effects reported with Wilzin, see the package leaflet.

Wilzin should not be used in people who may be hypersensitive (allergic) to zinc or any of the other ingredients.

## Why has Wilzin been approved?

The Committee for Medicinal Products for Human Use (CHMP) noted that Wilson's disease is a fatal disease and the other medicines already being used for the disease can have severe side effects. Therefore, the Committee decided that Wilzin's benefits are greater than its risks for the treatment of Wilson's disease. The Committee recommended that Wilzin be given marketing authorisation.

## Other information about Wilzin

The European Commission granted a marketing authorisation valid throughout the European Union for Wilzin to Orphan Europe SARL on 13 October 2004. The marketing authorisation was renewed on 13 October 2009.

Wilzin : EPAR - Summary for the public

English (EN) (40.23 KB - PDF)

**First published:** 12/09/2006

**Last updated:** 12/01/2010

[View](/en/documents/overview/wilzin-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-245)

български (BG) (172.39 KB - PDF)

**First published:**

12/09/2006

**Last updated:**

12/01/2010

[View](/bg/documents/overview/wilzin-epar-summary-public_bg.pdf)

español (ES) (56.25 KB - PDF)

**First published:**

12/09/2006

**Last updated:**

12/01/2010

[View](/es/documents/overview/wilzin-epar-summary-public_es.pdf)

čeština (CS) (163.9 KB - PDF)

**First published:**

12/09/2006

**Last updated:**

12/01/2010

[View](/cs/documents/overview/wilzin-epar-summary-public_cs.pdf)

dansk (DA) (48.57 KB - PDF)

**First published:**

12/09/2006

**Last updated:**

12/01/2010

[View](/da/documents/overview/wilzin-epar-summary-public_da.pdf)

Deutsch (DE) (49.24 KB - PDF)

**First published:**

12/09/2006

**Last updated:**

12/01/2010

[View](/de/documents/overview/wilzin-epar-summary-public_de.pdf)

eesti keel (ET) (55.3 KB - PDF)

**First published:**

12/09/2006

**Last updated:**

12/01/2010

[View](/et/documents/overview/wilzin-epar-summary-public_et.pdf)

ελληνικά (EL) (196.72 KB - PDF)

**First published:**

12/09/2006

**Last updated:**

12/01/2010

[View](/el/documents/overview/wilzin-epar-summary-public_el.pdf)

français (FR) (49.18 KB - PDF)

**First published:**

12/09/2006

**Last updated:**

12/01/2010

[View](/fr/documents/overview/wilzin-epar-summary-public_fr.pdf)

italiano (IT) (41.33 KB - PDF)

**First published:**

12/09/2006

**Last updated:**

12/01/2010

[View](/it/documents/overview/wilzin-epar-summary-public_it.pdf)

latviešu valoda (LV) (184.98 KB - PDF)

**First published:**

12/09/2006

**Last updated:**

12/01/2010

[View](/lv/documents/overview/wilzin-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (165.85 KB - PDF)

**First published:**

12/09/2006

**Last updated:**

12/01/2010

[View](/lt/documents/overview/wilzin-epar-summary-public_lt.pdf)

magyar (HU) (161.51 KB - PDF)

**First published:**

12/09/2006

**Last updated:**

12/01/2010

[View](/hu/documents/overview/wilzin-epar-summary-public_hu.pdf)

Malti (MT) (182.97 KB - PDF)

**First published:**

12/09/2006

**Last updated:**

12/01/2010

[View](/mt/documents/overview/wilzin-epar-summary-public_mt.pdf)

Nederlands (NL) (48.7 KB - PDF)

**First published:**

12/09/2006

**Last updated:**

12/01/2010

[View](/nl/documents/overview/wilzin-epar-summary-public_nl.pdf)

polski (PL) (167.96 KB - PDF)

**First published:**

12/09/2006

**Last updated:**

12/01/2010

[View](/pl/documents/overview/wilzin-epar-summary-public_pl.pdf)

português (PT) (48.9 KB - PDF)

**First published:**

12/09/2006

**Last updated:**

12/01/2010

[View](/pt/documents/overview/wilzin-epar-summary-public_pt.pdf)

română (RO) (152.23 KB - PDF)

**First published:**

12/09/2006

**Last updated:**

12/01/2010

[View](/ro/documents/overview/wilzin-epar-summary-public_ro.pdf)

slovenčina (SK) (159.37 KB - PDF)

**First published:**

12/09/2006

**Last updated:**

12/01/2010

[View](/sk/documents/overview/wilzin-epar-summary-public_sk.pdf)

slovenščina (SL) (119.25 KB - PDF)

**First published:**

12/09/2006

**Last updated:**

12/01/2010

[View](/sl/documents/overview/wilzin-epar-summary-public_sl.pdf)

Suomi (FI) (55.59 KB - PDF)

**First published:**

12/09/2006

**Last updated:**

12/01/2010

[View](/fi/documents/overview/wilzin-epar-summary-public_fi.pdf)

svenska (SV) (48.37 KB - PDF)

**First published:**

12/09/2006

**Last updated:**

12/01/2010

[View](/sv/documents/overview/wilzin-epar-summary-public_sv.pdf)

## Product information

Wilzin : EPAR - Product Information

English (EN) (388.55 KB - PDF)

**First published:** 11/10/2007

**Last updated:** 18/12/2024

[View](/en/documents/product-information/wilzin-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-455)

български (BG) (431.87 KB - PDF)

**First published:**

11/10/2007

**Last updated:**

18/12/2024

[View](/bg/documents/product-information/wilzin-epar-product-information_bg.pdf)

español (ES) (379.64 KB - PDF)

**First published:**

11/10/2007

**Last updated:**

18/12/2024

[View](/es/documents/product-information/wilzin-epar-product-information_es.pdf)

čeština (CS) (439.95 KB - PDF)

**First published:**

11/10/2007

**Last updated:**

18/12/2024

[View](/cs/documents/product-information/wilzin-epar-product-information_cs.pdf)

dansk (DA) (385.93 KB - PDF)

**First published:**

11/10/2007

**Last updated:**

18/12/2024

[View](/da/documents/product-information/wilzin-epar-product-information_da.pdf)

Deutsch (DE) (438.15 KB - PDF)

**First published:**

11/10/2007

**Last updated:**

18/12/2024

[View](/de/documents/product-information/wilzin-epar-product-information_de.pdf)

eesti keel (ET) (385.7 KB - PDF)

**First published:**

11/10/2007

**Last updated:**

18/12/2024

[View](/et/documents/product-information/wilzin-epar-product-information_et.pdf)

ελληνικά (EL) (494.8 KB - PDF)

**First published:**

11/10/2007

**Last updated:**

18/12/2024

[View](/el/documents/product-information/wilzin-epar-product-information_el.pdf)

français (FR) (387.9 KB - PDF)

**First published:**

11/10/2007

**Last updated:**

18/12/2024

[View](/fr/documents/product-information/wilzin-epar-product-information_fr.pdf)

hrvatski (HR) (459.23 KB - PDF)

**First published:**

11/10/2007

**Last updated:**

18/12/2024

[View](/hr/documents/product-information/wilzin-epar-product-information_hr.pdf)

íslenska (IS) (348.86 KB - PDF)

**First published:**

11/10/2007

**Last updated:**

18/12/2024

[View](/is/documents/product-information/wilzin-epar-product-information_is.pdf)

italiano (IT) (375.25 KB - PDF)

**First published:**

11/10/2007

**Last updated:**

18/12/2024

[View](/it/documents/product-information/wilzin-epar-product-information_it.pdf)

latviešu valoda (LV) (426.53 KB - PDF)

**First published:**

11/10/2007

**Last updated:**

18/12/2024

[View](/lv/documents/product-information/wilzin-epar-product-information_lv.pdf)

lietuvių kalba (LT) (440.78 KB - PDF)

**First published:**

11/10/2007

**Last updated:**

18/12/2024

[View](/lt/documents/product-information/wilzin-epar-product-information_lt.pdf)

magyar (HU) (445.11 KB - PDF)

**First published:**

11/10/2007

**Last updated:**

18/12/2024

[View](/hu/documents/product-information/wilzin-epar-product-information_hu.pdf)

Malti (MT) (479.42 KB - PDF)

**First published:**

11/10/2007

**Last updated:**

18/12/2024

[View](/mt/documents/product-information/wilzin-epar-product-information_mt.pdf)

Nederlands (NL) (362.87 KB - PDF)

**First published:**

11/10/2007

**Last updated:**

18/12/2024

[View](/nl/documents/product-information/wilzin-epar-product-information_nl.pdf)

norsk (NO) (373.26 KB - PDF)

**First published:**

11/10/2007

**Last updated:**

18/12/2024

[View](/no/documents/product-information/wilzin-epar-product-information_no.pdf)

polski (PL) (488.7 KB - PDF)

**First published:**

11/10/2007

**Last updated:**

18/12/2024

[View](/pl/documents/product-information/wilzin-epar-product-information_pl.pdf)

português (PT) (443.09 KB - PDF)

**First published:**

11/10/2007

**Last updated:**

18/12/2024

[View](/pt/documents/product-information/wilzin-epar-product-information_pt.pdf)

română (RO) (455.9 KB - PDF)

**First published:**

11/10/2007

**Last updated:**

18/12/2024

[View](/ro/documents/product-information/wilzin-epar-product-information_ro.pdf)

slovenčina (SK) (462.04 KB - PDF)

**First published:**

11/10/2007

**Last updated:**

18/12/2024

[View](/sk/documents/product-information/wilzin-epar-product-information_sk.pdf)

slovenščina (SL) (550.93 KB - PDF)

**First published:**

11/10/2007

**Last updated:**

18/12/2024

[View](/sl/documents/product-information/wilzin-epar-product-information_sl.pdf)

Suomi (FI) (383.26 KB - PDF)

**First published:**

11/10/2007

**Last updated:**

18/12/2024

[View](/fi/documents/product-information/wilzin-epar-product-information_fi.pdf)

svenska (SV) (382.19 KB - PDF)

**First published:**

11/10/2007

**Last updated:**

18/12/2024

[View](/sv/documents/product-information/wilzin-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0036/G 16/12/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Wilzin : EPAR - All Authorised presentations

English (EN) (59.79 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/all-authorised-presentations/wilzin-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-182)

български (BG) (41.32 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/bg/documents/all-authorised-presentations/wilzin-epar-all-authorised-presentations_bg.pdf)

español (ES) (58.41 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/es/documents/all-authorised-presentations/wilzin-epar-all-authorised-presentations_es.pdf)

čeština (CS) (81.02 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/cs/documents/all-authorised-presentations/wilzin-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (61.04 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/da/documents/all-authorised-presentations/wilzin-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (61.95 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/de/documents/all-authorised-presentations/wilzin-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (58.89 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/et/documents/all-authorised-presentations/wilzin-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (75.1 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/el/documents/all-authorised-presentations/wilzin-epar-all-authorised-presentations_el.pdf)

français (FR) (58.77 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/fr/documents/all-authorised-presentations/wilzin-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (34.98 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/hr/documents/all-authorised-presentations/wilzin-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (21.81 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/is/documents/all-authorised-presentations/wilzin-epar-all-authorised-presentations_is.pdf)

italiano (IT) (57.5 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/it/documents/all-authorised-presentations/wilzin-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (80.66 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/lv/documents/all-authorised-presentations/wilzin-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (79.71 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/lt/documents/all-authorised-presentations/wilzin-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (78.92 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/hu/documents/all-authorised-presentations/wilzin-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (33.53 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/mt/documents/all-authorised-presentations/wilzin-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (60.22 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/nl/documents/all-authorised-presentations/wilzin-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (21.83 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/no/documents/all-authorised-presentations/wilzin-epar-all-authorised-presentations_no.pdf)

polski (PL) (85.03 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/pl/documents/all-authorised-presentations/wilzin-epar-all-authorised-presentations_pl.pdf)

português (PT) (58.01 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/pt/documents/all-authorised-presentations/wilzin-epar-all-authorised-presentations_pt.pdf)

română (RO) (36.72 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/ro/documents/all-authorised-presentations/wilzin-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (81.91 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/sk/documents/all-authorised-presentations/wilzin-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (79.36 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/sl/documents/all-authorised-presentations/wilzin-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (58.44 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/fi/documents/all-authorised-presentations/wilzin-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (60.51 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/sv/documents/all-authorised-presentations/wilzin-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Wilzin Active substance zinc International non-proprietary name (INN) or common name zinc Therapeutic area (MeSH) Hepatolenticular Degeneration Anatomical therapeutic chemical (ATC) code A16AX05

### Pharmacotherapeutic group

Other alimentary tract and metabolism products

### Therapeutic indication

Treatment of Wilson's disease.

## Authorisation details

EMA product number EMEA/H/C/000535 Marketing authorisation holder

Recordati Rare Diseases

Immeuble le Wilson

Marketing authorisation issued 12/10/2004 Revision 12

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Wilzin : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (143.82 KB - PDF)

**First published:** 11/10/2007

**Last updated:** 18/12/2024

[View](/en/documents/procedural-steps-after/wilzin-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Wilzin : EPAR - Scientific Discussion

English (EN) (431.34 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/scientific-discussion/wilzin-epar-scientific-discussion_en.pdf)

#### More information on Wilzin

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu301050) on 30 July 2001. Wilzin has been removed from the Community register of orphan medicinal products, at the end of the period of market exclusivity.

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 18/12/2024

## Share this page

[Back to top](#main-content)